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Clinics and pathology 
Phenotype / cell stem origin 
Generally found in alveolar rhabdomyosarcoma 
(ARMS); also found in rare cases diagnosed as 
embryonal rhabdomyosarcoma (ERMS). 
Epidemiology 
Occurs in ~20% ARMS cases and <5% of ERMS 
cases: patients tend to be younger children compared to 
those with t(2;13)-positive ARMS tumors. 
Clinics 
Tumors tend to show lower invasiveness compared to 
those with t(2;13)-positive ARMS tumors. In metastatic 
cases, there is a low incidence of bone marrow 
involvement. 
Prognosis 
In one study, patients with localized t(2;13) and 
t(1;13)-positive ARMS had comparable outcomes 
whereas a recent study with small numbers suggested 
that localized t(1;13) tumors had a better outcome than 
those with localized t(2;13) tumors. Among patients 
presenting with metastatic disease, those with t(1;13)-
positive tumors had a significantly better outcome than 
those with t(2;13)-positive tumors. Note: these studies 
are based on molecular detection of the translocations. 
Cytogenetics 
Cytogenetics Morphological 
Though a balanced 1;13 is sometimes visible in cases 
with the associated molecular fusion event, in many 
 
 
cases the balanced translocation is not visible. Instead  
the molecular fusion is found associated with a 
subsequent amplification event, usually double minute 
chromosomes. 
 
Diagram of t(1;13)(p36;q14) chromosomal translocation. 
Cytogenetics Molecular 
The product of the 1;13 translocation is amplified in 
~90% of t(1;13)-positive cases. 
Additional anomalies 
Amplification events involving 2p24 and 13q31 (as 
determined by DNA-based array studies). 
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Transcription factor - forkhead box (FOX) family. 




The 1;13 translocation breaks within intron 7 of the 
PAX7 gene and intron 1 of the FOXO1 gene on 
chromosome 13 to generate a PAX7-FOXO1 fusion 
gene as well as a reciprocal FOXO1-PAX7 fusion 
gene. In ~55% of PAX7-FOXO1-positive ARMS 
tumors, this FOXO1-PAX3 gene is not detectable. In 
cases with fusion gene amplification, the PAX7-
FOXO1 fusion gene is amplified whereas the reciprocal 
FOXO1-PAX7 fusion gene is not. 
Transcript 
The PAX7-FOXO1 fusion transcript consists of the 
first 7 exons of PAX3 fused to FOXO1 exons 2 and 3. 
There is evidence that the PAX7-FOXO1 fusion 
transcript is upregulated relative to the wild-type PAX7 
transcript, presumably due to increased copy number of 
the fusion gene by amplification. 
Fusion Protein 
Description 
The fusion gene has a 2484 nt open reading frame 
encoding an 828 amino acid fusion protein. This fusion 
protein is a transcription factor with a PAX7 DNA 
binding domain and FOXO1 transactivation domain. 
Expression / Localisation 
Nuclear. 
Oncogenesis 
Transcription dysregulation. At the cellular level there 
is evidence of alterations in control of growth. In 
conjunction with other genetic changes, recipient cells 
show transformation in culture and tumorigenesis in 
injected mice. 
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